CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of
investigational RNA interference (RNAi) therapeutics, today announced
that Douglas M. Fambrough, Ph.D., president and chief executive officer,
will present at the following investor conferences in September.
Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday,
September 13, 2016 at 2:35-3:00 p.m. ET at the Lotte New York Palace
Hotel in New York City.
Leerink Partners Rare Disease and Immuno-Oncology Roundtable Series on
Wednesday, September 28, 2016 at 10:35-11:00 a.m. ET at the Lotte New
York Palace Hotel in New York City.
A live webcast of each presentation can be accessed on the Investors &
Media section of the Dicerna website at www.dicerna.com.
An archived replay of the webcasts will be available on the Company's
website after each conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is an RNA interference-based
biopharmaceutical company focused on the discovery and development of
innovative treatments for rare, inherited diseases involving the liver,
for other therapeutic areas in which the liver plays a key role, and for
cancers that are genetically defined. The Company is using its
proprietary RNA interference (RNAi) technology platform to build a broad
pipeline in these therapeutic areas. In many cases, Dicerna is pursuing
targets that have historically been difficult to inhibit using
conventional approaches, but where connections between targets and
diseases are well understood and documented. The Company intends to
discover, develop and commercialize these novel therapeutics either on
its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906006382/en/
Rx Communications Group
Van Rees, 973-442-1555, ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media